Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer (NSCLC) who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.